{"id":"W1966385883","doi":"10.1007/s10549-014-3221-2","title":"Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study","year":2014,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital du Saint-Sacrement; Ottawa Regional Cancer Foundation; Montreal General Hospital; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal","funders":"NSABP Foundation; GlaxoSmithKline","keywords":"Pazopanib; Medicine; Cyclophosphamide; Oncology; Breast cancer; Paclitaxel; Doxorubicin; Internal medicine; Neoadjuvant therapy; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001627158,0.001416828,0.002850471,0.0007072937,0.0004574648,0.001237632,0.001159091,0.00135783,0.002729245],"category_scores_gemma":[0.00111636,0.0008713582,0.00161243,0.0006890798,0.001330511,0.001445758,0.0004426153,0.00433417,0.001078445],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001063916,"about_ca_system_score_gemma":0.001756158,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001647237,"about_ca_topic_score_gemma":0.00587708,"domain_scores_codex":[0.9994221,0.0002282308,0.00003394646,0.0001021119,0.00006298599,0.0001506093],"domain_scores_gemma":[0.9991242,0.0001527576,0.0001446607,0.0001051651,0.00003008177,0.0004430044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7577937,0.09852014,0.003875083,0.0005095765,0.001153803,0.0002029261,0.0002223472,0.003359227,0.02090135,0.0002040789,0.001635757,0.1116221],"study_design_scores_gemma":[0.4286753,0.5522597,0.01151229,0.00004438225,0.0006015932,0.000350706,0.00006928566,0.001290796,0.003210972,0.0001641402,0.001774609,0.00004624575],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951133,0.001473798,0.0003074351,0.0002370098,0.0001281194,0.0008221272,0.0004455683,0.00007255728,0.001400059],"genre_scores_gemma":[0.9889698,0.003172328,0.001482098,0.0004457642,0.0002567118,0.001138801,0.001530122,0.00004780306,0.002956657],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002850471,"threshold_uncertainty_score":0.00913018,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04808848182568354,"score_gpt":0.4395269584767557,"score_spread":0.3914384766510721,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}